Skip to main content

Advertisement

Table 6 Frequency distribution by group of dogs with abnormalities recorded following the first treatment

From: Safety of fluralaner chewable tablets (BravectoTM), a novel systemic antiparasitic drug, in dogs after oral administration

Time point No. of animals with abnormalities recorded per group Analysis Conclusion
Control group 1X group 3X group 5X group
Clinical assessment 2 5 1 1 Number of animals with abnormalities higher in 1X group than in controls, but similar to controls in 3X and 5X group; no dose–response relationship Not treatment related
Physical examination 4 4 4 3 Number of animals with abnormalities similar to controls; no dose–response relationship Not treatment related